Cancer journeys: Research from India

Ms. Soumita Ghose - Tata Medical Center, Kolkata
Cancer journeys: Research from India ( Ms. Soumita Ghose - Tata Medical Center, Kolkata )
7 Sep 2024

Depression in cancer

Ms. Bidisha Samanta - Rocket Health, Kolkata, India
Depression in cancer ( Ms. Bidisha Samanta - Rocket Health, Kolkata, India )
7 Sep 2024

Managing 'fear of recurrence' of cancer patients

Ms Bincy Mathew - Manipal Hospitals, Bangalore, India
Managing 'fear of recurrence' of cancer patients ( Ms Bincy Mathew - Manipal Hospitals, Bangalore, India )
7 Sep 2024

Psychological issues in familial cancer

Dr Arnab Mukherjee - Tata Medical Center, Kolkata, India
Psychological issues in familial cancer ( Dr Arnab Mukherjee - Tata Medical Center, Kolkata, India )
7 Sep 2024

Colon cancer and mental health

Prof V Surendran- Cancer Institute, Chennai, India
Colon cancer and mental health ( Prof V Surendran- Cancer Institute, Chennai, India )
7 Sep 2024

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC

Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC ( Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium )
25 Jul 2024

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC

Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC ( Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France )
24 Jul 2024

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )
15 Jul 2024

Research highlights in gastrointestinal tumours

Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA
Research highlights in gastrointestinal tumours ( Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA )
12 Jul 2024

Updates from ASCO 2024 in gastrointestinal tumours

Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, USA
Updates from ASCO 2024 in gastrointestinal tumours ( Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, USA )
12 Jul 2024

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC

Prof David Tougeron - Poitiers University Hospital, Poitiers, France
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC ( Prof David Tougeron - Poitiers University Hospital, Poitiers, France )
9 Jul 2024

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer

Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer ( Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy )
9 Jul 2024